Navigation Links
Varian Medical Systems and Stanford University Win $3.6 Million Five-Year NIH/NCI Research Grant to Develop Advanced Imaging Technology

PALO ALTO, Calif., Oct. 11 /PRNewswire/ -- Scientists from Stanford University and from the Ginzton Technology Center at Varian Medical Systems have jointly received a $3.6 million five-year research grant from the U.S. National Institutes of Health (NIH) to develop advanced imaging technology for improving the quality of CT images for patients with metal objects in their bodies such as hip implants and dental fillings.  

The grant award is from the Cancer Imaging Program (CIP) of the National Cancer Institute (NCI) within NIH. The CIP made the grant under its program entitled: Academic-Industrial Partnerships for Development and Validation of In Vivo Imaging Systems and Methods for Cancer Investigations, which was set up to encourage inter-disciplinary research by industry and academia into cancer-related imaging challenges. Josh Star-Lack, Ph.D., a senior scientist in Varian's Ginzton Technology Center for research and development, and Rebecca Fahrig, Ph.D., associate professor of radiological sciences at the Stanford University School of Medicine, will serve as co-principal investigators on the project.  

"Modern radiotherapy of cancer often relies on high quality CT images for planning advanced forms of treatment," said Star-Lack.  "You also need good cone-beam CT images from a machine-mounted imager for patient positioning and for assessing tumor response to treatment.  These CT images are typically acquired at kilovoltage X-ray energies resulting in excellent soft tissue definition, which means you can distinguish tumor from muscle, fat, or other organs. Unfortunately, severe image distortions can be created when metal is present, making it harder to know what you're looking at."

According to Star-Lack, it is possible to greatly reduce the distortions by using very high energy (megavoltage) x-rays that better penetrate the metal.  However, megavoltage imaging also has significant disadvantages.  "You need a lot of dose, and the quality of images is poor, particularly in soft tissues," Star-Lack said.  "Our research grant will be used to develop tools to achieve the best of both worlds by combining kilovoltage cone-beam CT data with a limited amount of megavoltage data to create a composite image with less distortion and good soft tissue resolution."

As part of the project, researchers from Varian and Stanford will develop new megavoltage X-ray detection hardware and image reconstruction software, and will validate the new technology in a clinical trial to be conducted by Stanford.

"The rapid translation of these advances into clinical practice could improve the accuracy of radiotherapy planning and image guidance for patients with metal objects near the targeted tumors," Fahrig said.  "This is a unique grant program that recognizes the special synergies that can happen when academic researchers, who often focus on pure science, collaborate with industrial researchers, who often emphasize product-oriented R&D with near-term commercial possibilities."

The Ginzton Technology Center (GTC) serves as Varian Medical Systems' central R&D organization, incubating new technologies, supporting product development for the company's business units, and conducting government or industry-sponsored research projects. The GTC's mandate is to focus on the investigation of development of new, disruptive, "breakout" technologies that will create significantly improved capabilities for Varian's customers.

About Varian Medical SystemsVarian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit Medical SystemsMeryl Ginsberg,

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... sauna parts and accessories. , Sauna accessories help improve the bather experience in ... personality. From basic styles for the purist looking for simplicity in design to ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... ... ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David Adcock ... , According to court documents, Adcock testified that on May 10, 2010 he sat ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced ... in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for ... years, Brillianteen has been a treasured tradition for numerous families in the Evanston ...
Breaking Medicine News(10 mins):